Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 3 1Phase 2 1Phase 1/2 1

Status

Completed 2Terminated 1Recruiting 1

Sponsor Class

OTHER 2NETWORK 1INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Plasma cell 4

Conditions

Multiple Myeloma 3Recurrence 1Immunoglobulin Light-chain Amyloidosis 1

Interventions

Dexamethasone 871Bortezomib 457Lenalidomide 456Cyclophosphamide 365Melphalan 272Calcium Dobesilate 263daratumumab 234pomalidomide 208carfilzomib 182fludarabine phosphate 140fludarabine 136Thalidomide 125Peripheral Blood Stem Cell Transplantation 119Filgrastim 114ixazomib 93Mycophenolic Acid 90Granulocyte Colony-Stimulating Factor 89Whole-Body Irradiation 87Busulfan 87dexamethasone acetate 86Tacrolimus 78dexamethasone 21-phosphate 74isatuximab 69Cyclosporine 68auricularum 67Prednisone 65elotuzumab 58belantamab mafodotin 57Antilymphocyte Serum 56Etoposide 53

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × darlin protein, Dictyostelium × Plasma cell × Clear all
NCT03180736 2025-12-19

EMN14

European Myeloma Network B.V.

Phase 3 Completed
304 enrolled 19 charts 1 FDA
Plasma cell

Multiple Myeloma

NCT06455748 2024-06-12

Daratumumab/Daratumumab and Hyaluronidase-fihj in Combination With Pomalidomide and Dexamethasone for the Treatment of Patients With Newly Diagnosed AL Amyloidosis: a Prospective, Multicenter, Single-arm Study

First Affiliated Hospital of Wenzhou Medical University

Phase NA Recruiting
20 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis

NCT03450057 2024-03-29

DARE

Hellenic Society of Hematology

Phase 2 Completed
38 enrolled 16 charts
Plasma cell

Multiple Myeloma, Recurrence

NCT03481556 2022-12-19

ANCHOR

Oncopeptides AB

Phase 1/2 Terminated
56 enrolled 22 charts
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡